MARATTO

article · Bioscience Reports

Effect of <i>Taraxacum officinale</i> extract on PI3K/Akt pathway in DMBA-induced breast cancer in albino rats

201842 citationsOpen accessKafr el-Sheikh University

In plain language

Investigation into the effects of dandelion extract on chemically induced breast cancer in albino rats demonstrates notable anticancer activity. In the animal model, administration of the chemical inducer elevated the cancer biomarker CA15-3 and stimulated excessive epithelial cell proliferation in mammary gland tissues, accompanied by hyperchromatic nuclei and heavy Bcl2 immunostaining. Providing dandelion extract for four weeks successfully normalised CA15-3 concentrations and ameliorated these abnormal structural tissue changes. The chemical induction also triggered the upregulation of several genes within the mammary tissue, specifically Pdk1, Akt1, Pik3r1, Map3k1, Erbb2, and Pik3ca. Subsequent extract treatment restored normal messenger RNA expression levels across these genes, with the exception of Pik3ra, which was upregulated. Overall, the botanical extract counteracted breast cancer growth and proliferation by modulating the PI3K and Akt signalling pathways.

Key takeaways

  • Four weeks of Taraxacum officinale extract normalised elevated CA15-3 levels in rats with chemically induced breast cancer.
  • The plant extract ameliorated excessive epithelial cell proliferation and abnormal Bcl2 protein expression in mammary gland tissues.
  • Treatment restored baseline messenger RNA levels for several upregulated genes including Pdk1, Akt1, Map3k1, Erbb2, and Pik3ca.
  • The extract suppressed breast cancer growth and proliferation through the regulation of PI3K and Akt signalling pathways.

Why it matters

Breast cancer research constantly seeks new therapeutic strategies, and botanical compounds offer significant opportunities for drug discovery. Demonstrating that a common herbal extract can restore critical cancer biomarkers, reverse tissue abnormalities, and regulate gene expression in animal models provides valuable biological evidence for the ongoing exploration of natural products in oncology.

Commercialisation angle

This research could inform pharmaceutical and nutraceutical developers interested in identifying plant-derived compounds that modulate the PI3K and Akt pathways in oncology. Because the findings are based entirely on early-stage animal testing in rats, the work remains far from clinical use. Substantial downstream research, including active compound isolation, toxicity profiling, and clinical trials, will be required before commercial therapeutics can be developed.

AI-generated from the published abstract. Always read the original work before citing.

Abstract

Level of CA15-3 was normalized in DMBA group administered TOE for 4 weeks. Administration of DMBA increased expression of <i>Pdk1, Akt1, Pik3r1, Map3k1, Erbb2 and PIk3ca</i> Treatment with TOE normalized the up-regulated mRNA for all examined genes except <i>Pik3ra</i> that was up-regulated. Mammary gland tissues of DMBA group showed excessive proliferation of lining epithelium of acini and ductules with hyperchromatic nuclei with excessive immunostaining of Bcl2 in the proliferated epithelium that was ameliorated by TOE administration. In conclusion, TOE regulated PI3K and Akt pathways involved in suppression of breast cancer growth and proliferation. TOE is effective as anticancer herbal agent.

Research topics

  • Sesquiterpenes and Asteraceae Studies
  • Natural product bioactivities and synthesis
  • Phytochemistry and biological activity of medicinal plants

Sustainable Development Goals

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.1042/bsr20180334

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.